AHK-Cu
Copper tripeptide (Ala-His-Lys-Cu)
AHK-Cu (Copper tripeptide (Ala-His-Lys-Cu)) is a healing & recovery research compound. Copper-binding peptide focused on hair — promotes follicle growth and dermal microvascularization; the hair-oriented cousin of GHK-Cu.
AHK-Cu quick facts
| Reported research dose (Topical) | 1mg-5mg |
| Route | Subq or topical |
| Frequency | 1x Daily |
| Half-life | Topical/local; short systemically |
| Forms | Injectable, Topical |
| Evidence level | In-vitro + topical |
| Other forms available | Injectable — dosed differently |
The hair peptide — run alongside or instead of GHK-Cu for the scalp.
How AHK-Cu works
Copper-binding peptide focused on hair — promotes follicle growth and dermal microvascularization; the hair-oriented cousin of GHK-Cu.
Proposed benefits
Hair growth and scalp/skin support (copper peptide).
Where to get AHK-Cu
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for AHK-Cu
Graded by what exists behind each claim.
✅ Clinically validated
- No trials of injected AHK-Cu. Topical copper-peptide research is the relevant human evidence, and small controlled work on AHK-Cu specifically reported increased hair follicle size and stimulated dermal papilla cell proliferation.
📊 Correlative data
- Used topically and by injection for hair growth, usually alongside GHK-Cu. Reported experience is of a slower, subtler effect than minoxidil, and the same local reaction at injection sites that every copper peptide produces.
🧪 Theoretical / extrapolated
- A copper-binding tripeptide (Ala-His-Lys) closely related to GHK-Cu, with activity weighted toward hair follicle rather than general dermal repair — it upregulates VEGF in dermal papilla cells.
- Copper delivery is the mechanism and the ceiling, exactly as with GHK-Cu: copper is tightly regulated systemically, so more is not straightforwardly better and topical use has a far better rationale than injection.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What AHK-Cu actually does
AHK-Cu is the tripeptide Ala-His-Lys carrying a single copper(II) ion, and the histidine in the middle is the reason the complex exists at all. The imidazole side chain of that histidine residue, the free N-terminal amine, and the deprotonated backbone amide nitrogen between the first two residues together form a chelating pocket that holds Cu(II) in a stable square-planar geometry. Change the histidine and there is no complex; change the alanine and you get GHK-Cu, its better-known cousin.
The copper coordination has been modeled rather than assumed. Computational work on the closely related GHK peptide examined how copper binds it and which donor atoms are involved Alshammari 2020. The reason that matters here is practical: the affinity and geometry of the complex determine whether the copper stays on the peptide when it meets a competing ligand, and blood is full of competing ligands.
What the complex does to a hair follicle, measured directly on human tissue. AHK-Cu at 10−12 to 10−9 M stimulated elongation of human hair follicles ex vivo and proliferation of dermal papilla cells in vitro. Flow cytometry showed a reduced number of apoptotic dermal papilla cells at 10−9 M, though not significantly; the Bcl-2/Bax ratio rose and the cleaved forms of caspase-3 and PARP fell Pyo 2007. The mechanism the authors propose is proliferation plus prevention of apoptosis in the dermal papilla — the cell population that decides how long a follicle stays in anagen.
Read the concentration range again, because it is the most important number on this page. Picomolar to nanomolar. This is not a compound that needs a large dose to work on a follicle — it works at concentrations three to six orders of magnitude below the ones typically injected. Whatever limits this compound, it is not potency. It is delivery, stability, and whether the copper is still attached to the peptide when it arrives.
The family context. The related tripeptide-copper complex GHK-Cu stimulates matrix metalloproteinase activity in fibroblasts Simeon 2000, and the free peptides and their copper complexes have been compared for effects on inflammatory signaling Gruchlik 2012. That last comparison matters: the peptide and the copper complex are not interchangeable, and a product that has lost its copper is a different molecule from the one that was tested.
Cell, rodent, human — and where it stops
Step one, human tissue ex vivo — which is a stronger starting point than most compounds here get. Human hair follicles in organ culture and human dermal papilla cells, with elongation, proliferation and apoptosis markers as endpoints Pyo 2007. Human tissue, human cells, defined concentrations. What it is not is a living person: an organ-cultured follicle has no circulation, no immune system and no androgen environment.
Step two, the cousin's biochemistry, which supplies the mechanism vocabulary. GHK-Cu's effect on matrix metalloproteinases in fibroblasts Simeon 2000 and the comparison of free peptides with their copper complexes on inflammatory cytokine handling Gruchlik 2012 are the closest thing to a mechanistic literature this family has. Both are cell work.
Step three, humans — and this is the gap. A 2026 review of short peptides for hair loss surveys the field and its limitations, noting that approved treatments carry side effects and that peptide approaches are promising but constrained, with formulation and nanosystem strategies proposed to address those constraints Fan 2026. There is no randomized controlled trial of AHK-Cu for hair loss in humans, by any route. Not topical, not injected.
The obstacle is a delivery problem with a number attached. The tested concentration range tops out at 1 nanomolar Pyo 2007. Take a 1 mg systemic dose of a complex with a formula mass near 400: that is roughly 2.5 micromoles, and if it distributed evenly through about 15 liters of extracellular fluid without being touched it would sit near 170 nanomolar — more than a hundred times the top of the range that worked on a follicle. Nobody has shown that higher is better for this molecule, and copper-peptide effects in culture are frequently bell-shaped rather than monotonic.
And the obstacle behind that obstacle: the copper does not necessarily arrive. Plasma copper is not free — it is held by ceruloplasmin and by albumin, and albumin's own N-terminal sequence is a well-known high-affinity Cu(II) binding site. Clearly labeled as extrapolation from coordination chemistry rather than from a measurement: injecting a 1:1 tripeptide-copper complex into a compartment containing a large molar excess of a competing copper acceptor should transfer a substantial fraction of the metal to albumin, leaving free tripeptide and albumin-bound copper — neither of which is what was tested Alshammari 2020Gruchlik 2012. That has never been measured for this compound and it is the single experiment that would decide whether systemic dosing can work at all.
AHK-Cu pharmacokinetics — how much of it actually gets in
The card says topical or local, short systemically, and gives no number. That is the right shape of answer, and here is the reasoning that produces it.
What degrades the peptide. Ala-His-Lys is a tripeptide with a free N-terminus and a free C-terminus, which makes it a substrate for serum aminopeptidases and carboxypeptidases with no protection whatever. Tripeptides of this class survive in plasma for minutes. The copper complex is somewhat more resistant than the free peptide because chelation rigidifies the backbone, but that is a modest effect, not a formulation strategy.
What happens to the metal is a separate and faster process than what happens to the peptide. Copper transfer between ligands is fast, and the relevant comparison is not stability in a vial but stability against the copper-binding proteins already in blood. Two clearance routes therefore run in parallel — proteolysis of the peptide and ligand exchange of the copper — and the complex is gone as a complex as soon as either completes.
The oral barrier, which for a tripeptide is not what people assume. Di- and tripeptides are the one peptide class with a genuine intestinal transporter: PepT1 in the brush border carries them into the enterocyte intact. So oral absorption of the free tripeptide is plausible in a way it is not for a 37-residue peptide. The problem is that intracellular peptidases hydrolyze most of what is carried in, and the copper almost certainly does not survive the journey attached — gastric acid alone will protonate the imidazole and weaken the coordination. An oral copper tripeptide is a copper supplement plus three amino acids unless somebody demonstrates otherwise.
Which is why topical is the route with a real argument. The human evidence is a follicle in organ culture bathed in a defined picomolar-to-nanomolar concentration Pyo 2007, and the route that reproduces that geometry is one that puts a low concentration next to the follicle and keeps it there. A subcutaneous injection delivers a large bolus to one location and a negligible systemic concentration everywhere else; the review literature's emphasis on formulation and delivery systems for peptide hair treatments is a response to exactly this problem Fan 2026.
What would have to be true, and how you would know it was not
Three predictions. The first two are copper-handling markers with real assays behind them; the third is the one that argues against the injected route.
1. Serum copper and ceruloplasmin should be measured before anything, and they should not move much afterwards. A milligram of a copper complex contains a small fraction of a milligram of copper, which is a modest addition to daily intake — but it is delivered past the intestine, which is where copper absorption is normally regulated. Prediction: copper and ceruloplasmin at baseline and at 12 weeks are within their reference intervals, with ceruloplasmin the more stable of the two. If serum copper climbs while ceruloplasmin does not, the excess is riding on albumin rather than being incorporated, and that is the fraction that matters toxicologically.
2. Zinc should be watched precisely because copper and zinc compete. The two metals share absorption and handling pathways, and sustained excess of one lowers the other. Prediction: plasma zinc at baseline and at 12 weeks drifts downward with repeated copper-peptide use, and it will do so silently. This is the cheapest way to detect that a copper compound is doing something systemic, and it is more sensitive than serum copper itself because copper is homeostatically defended and zinc is the one that yields.
3. Against the injected route: hair count should respond to topical and not to systemic, at matched total dose. The follicle evidence is a local concentration effect in the picomolar-to-nanomolar range Pyo 2007, and the arithmetic above says an injection either overshoots that range enormously at the depot or falls far short of it elsewhere. Prediction: in a within-person comparison — one side of the scalp treated topically, the other not, standardized photography at 0, 3 and 6 months — the topical side shows a difference and a systemic dose does not add to it. There is no blood marker for hair; the instrument is a camera under fixed lighting, and without a baseline photograph the whole experiment is uninterpretable.
What nobody has tested yet
Four experiments that would move this compound from plausible to known.
Whether the copper stays on the peptide in blood. This is the first question and nobody has answered it. A simple ligand-exchange experiment — the complex incubated in human serum, copper speciation measured over time — would say whether systemic dosing delivers the tested molecule or its two separated halves Alshammari 2020.
Whether the dose-response is monotonic or bell-shaped. The human follicle work used 10−12 to 10−9 M Pyo 2007 and did not extend upward. Copper complexes are frequently biphasic, growth-promoting at low concentration and cytotoxic above it. Testing three more log units in the same organ-culture model is a small experiment with a large practical consequence for anyone choosing a dose.
Whether AHK-Cu and GHK-Cu do the same thing to a follicle. They differ by one residue — alanine for glycine at position 1 — and the GHK literature is about matrix and fibroblasts Simeon 2000 while the AHK work is about dermal papilla Pyo 2007. Whether that reflects a real difference in target cell or simply which experiment each group ran is unresolved, and one side-by-side comparison in one model would settle it.
Whether it does anything in a person with androgenetic hair loss. Every human data point is ex vivo. A within-person split-scalp trial with standardized photography, macrophotographic hair counts and six months of follow-up is an ordinary dermatology design, it is what the review literature implicitly calls for Fan 2026, and it has not been published for this molecule.
AHK-Cu — its own safety story, not its class's
The risk here is copper, and it is a slow risk rather than an acute one.
Copper is an essential metal with a narrow useful range. Too little causes anemia and neutropenia; too much causes hepatic injury and, at extremes, hemolysis. The body regulates it mainly at absorption in the gut, which is the step that an injection bypasses entirely. That is the mechanistic reason a systemic copper peptide deserves a metal panel and a topical one broadly does not.
The population that must not use this is defined by genetics, not by dose. Anyone with Wilson disease, or an unexplained elevated liver enzyme profile with a low ceruloplasmin, is a person whose copper excretion is already impaired. Adding parenteral copper to that is not a matter of degree. It is also not rare enough to ignore, and the test that identifies it is inexpensive.
The zinc consequence is the one that shows up first in a healthy person. Copper and zinc antagonize each other in absorption and in metallothionein handling, and a sustained copper load lowers zinc long before it raises copper out of range. Low zinc is itself associated with hair shedding, which produces the unpleasant possibility of a copper peptide taken for hair causing hair loss through the metal it delivers.
What the injectable route adds that topical does not. A topical copper tripeptide delivers a small quantity through an absorptive barrier to the tissue that was studied Pyo 2007. An injection delivers the whole quantity past every regulatory step to a site that is not the target, and there is no human trial of the injected route at all Fan 2026. The route with the evidence and the route with the risk are not the same route, and that is the sentence this page exists to make.
Sources read for this page
- Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007 · PMID 17703734
- Fan C, Zhang Y, Wang J. Overview of Short Peptides for Hair Loss. Biomedicines 2026 · PMID 42072405
- Simeon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci 2000 · PMID 11045606
- Alshammari N, Platts JA. Theoretical study of copper binding to GHK peptide. Comput Biol Chem 2020 · PMID 32371360
- Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm 2012 · PMID 23285694
AHK-Cu — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- The copper is the active ingredient and also the constraint. Copper is an essential trace mineral with a genuine upper limit, and these deliver it directly.
- Topically over a small area this is not a systemic concern. Large surface areas, high concentrations, or injecting it are a different proposition — the same molecule at a different exposure.
What has actually been reported
- Topical use is well tolerated; irritation and temporary blue-green staining are the common complaints, both cosmetic.
How to reduce the risk
Same mechanism as the prediction.
- Match the exposure to the goal. A face-sized area of a topical is a different proposition from full-body use or injection. Most of the cosmetic benefit is local, so there is rarely a reason to escalate to systemic exposure for a skin outcome.
- Keep it away from direct vitamin C in the same layer. Copper and ascorbic acid deactivate each other — this wastes both rather than harming you, but it is the most common way people get nothing from an expensive product. Vitamin C in the morning, copper at night.
- Don't stack multiple copper products at once. A copper serum, a copper shampoo and a copper body lotion are three doses of the same mineral, and the ceiling is on the mineral, not on the product.
- If you are injecting it or covering large areas long-term, serum copper and ceruloplasmin are the two markers that would actually show accumulation.
What it does to your bloodwork
A fact about the assay.
- If you are using this at scale or injecting it, serum copper and ceruloplasmin are the markers that would show accumulation.
Don't run this if
- Wilson's disease or any condition of copper handling — the mechanism is delivering the exact thing you cannot clear.
The honest unknown
- Cumulative copper load from long-term high-surface-area topical use has not been characterized.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
AHK-Cu — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What AHK-Cu moves on your bloodwork
Expected direction, not a measured one.
- Copper, Serum — ↑ expected to rise
Only relevant at systemic doses — topical use does not meaningfully raise serum copper.
What to do: Not routinely needed. It matters if you are injecting it regularly or already have a copper-handling condition. - Ceruloplasmin — ◆ worth watching
The copper-carrying protein, and the one that tells you whether copper is bound and safe or free and reactive.
What to do: Read with serum copper, never alone. - Zinc, Plasma — ↓ expected to fall
Copper and zinc compete for absorption. Sustained copper loading predicts falling zinc, which then shows up as immune and taste changes that get blamed on something else.
What to do: If you are running copper systemically for months, check zinc.
- How to work up to it, and when not to
- When to take it, and why that window
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — AHK-Cu in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside AHK-Cu
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
AHK-Cu — frequently asked questions
What is AHK-Cu?
AHK-Cu (Copper tripeptide (Ala-His-Lys-Cu)) is a healing & recovery research compound. Copper-binding peptide focused on hair — promotes follicle growth and dermal microvascularization; the hair-oriented cousin of GHK-Cu.
Is the full AHK-Cu protocol on this page?
The reported research dose is on this page, along with how AHK-Cu works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of AHK-Cu?
AHK-Cu has an approximate half-life of Topical/local; short systemically, which is part of what determines how often it's dosed.
What forms does AHK-Cu come in?
AHK-Cu is available as: Injectable, Topical.
What's the evidence behind AHK-Cu?
Current evidence level: In-vitro + topical. AHK-Cu is offered for research purposes only and is not an approved medicine.
AHK-Cu inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What AHK-Cu is used for
AHK-Cu appears under 1 goal in the goal router.
Related Healing & Recovery compounds
Where this goes next
AHK-Cu is the hair arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.